Clarity Pharmaceuticals Ltd.ASX: CU6

IND Approval by US FDA for Phase II SAR-Bombesin trial

Jun 6, 2022 at 3:52 AM UTC · Issued by Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd has released a press release.

View Attachment